The phase III ATTRACTION-2 study evaluated PD-1 inhibitor nivolumab for repeatedly treated advanced-stage gastric and gastroesophageal junction (G/GEJ) cancer.609 According to 2-year follow-up results, OS was significantly longer in the nivolumab group regardless of tumor PD-L1 expression.609 In the phase III KEYNOTE-062 trial, the PD-1 inhibitor pembrolizumab, alone or in combination with chemotherapy, was tested as first-line therapy in advanced GC. This evidence concerns the gene CD274 and neoplasm.